Can I Take L-Theanine With PT-141 (Bremelanotide)?
At a glance
- Human interaction data / no L-theanine drug-interaction or CYP studies found [2]
- Approved bremelanotide / Vyleesi, 1.75 mg subcutaneous autoinjector [1]
- Label blood pressure effect / maximal rise of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose [1]
- Label heart rate effect / reduction of up to 5 beats per minute [1]
- Mean effect over 8 daily doses / 1.9 mmHg systolic and 1.7 mmHg diastolic; heart rate 0.5 beats per minute lower [1]
- L-theanine status / over-the-counter supplement; no FDA-approved drug application [3]
- L-theanine blood pressure data / blunts stress-related rises in small studies; resting effect not established [4][5]
- Compounded PT-141 / not Vyleesi and not an FDA-approved drug [6]
What each one actually is
Bremelanotide is FDA-approved as Vyleesi (NDA 210557, approved June 21, 2019): a 1.75 mg subcutaneous autoinjector for premenopausal women with acquired, generalized hypoactive sexual desire disorder — low desire that causes marked distress or interpersonal difficulty and is not explained by a medical or psychiatric condition, relationship problems, or another drug [1][7]. The label says it is not indicated for postmenopausal women or for men, and not to enhance sexual performance [1]. A dose goes into the abdomen or thigh at least 45 minutes before anticipated sexual activity, no more than once in 24 hours, and more than 8 doses a month is not recommended; the label says to stop after 8 weeks if symptoms have not improved [1].
It is a cyclic peptide of 7 amino acids that activates melanocortin receptors nonselectively, in this order of potency: MC1R, MC4R, MC3R, MC5R, MC2R, with MC1R and MC4R binding most relevant at the approved dose. How it improves desire is unknown [1].
Vyleesi is the FDA-approved bremelanotide product. Compounded or research-use products sold as PT-141 are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][6].
L-theanine is an amino acid found mainly in tea leaves, sold over the counter and added to foods and drinks. A Drugs@FDA search returns no approved drug application with theanine as the active ingredient, so it is not an FDA-approved treatment for anxiety, sleep or any other condition [3]. In 2007 FDA closed a notice in which a company concluded L-theanine was generally recognized as safe for several food categories at up to 250 mg per serving, responding that it had no questions; that response is not an approval, and FDA does not make its own GRAS determination [8].
Is there a known interaction between L-theanine and bremelanotide?
The Vyleesi label does not name L-theanine in its drug interactions section [1]. No human drug-interaction or CYP-enzyme study of L-theanine was found [2], so whether theanine changes bremelanotide exposure or its blood-pressure effect, or the reverse, has not been measured.
Metabolism. The label describes bremelanotide as metabolized by hydrolysis of amide bonds, with 64.8% of radioactivity recovered in urine and 22.8% in feces [1]. After a 1.75 mg subcutaneous dose, mean Cmax is 72.8 ng/mL, median time to peak is about 1 hour, and mean terminal half-life is about 2.7 hours, with a range of 1.9 to 4.0 hours [1].
Absorption. Bremelanotide may slow gastric emptying and reduce absorption of oral medicines. The label says to avoid it with oral drugs that depend on threshold blood concentrations, such as antibiotics, and to consider skipping it when a quick effect from an oral medicine such as indomethacin is wanted; in clinical pharmacology studies only naltrexone and indomethacin were meaningfully affected, and the label says to avoid oral naltrexone products intended to treat alcohol or opioid addiction [1].
Blood pressure and heart rate: where the two could overlap
Bremelanotide transiently raises blood pressure and lowers heart rate after every dose. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the injection, with heart rate down up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. Those are maximal, not average, figures. In an open-label ambulatory study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1]. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease, and the label says to consider cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment [1].
L-theanine's human blood-pressure data are small and come from stress testing rather than from trials in people with hypertension. In a study of 14 participants it significantly blunted the blood-pressure rise during mental tasks among participants whose pressure rose more than average, and lowered tension-anxiety scores [4]. In 48 adults, 200 mg of theanine antagonized the blood-pressure rise caused by 250 mg of caffeine but did not significantly change jitteriness or alertness [5]. In 12 participants it reduced heart rate and salivary immunoglobulin A responses to mental arithmetic [9]. L-theanine is described as blocking the binding of glutamate to glutamate receptors in the brain, which researchers propose reduces cortical neuron excitation; the exact mechanism in people is not settled [9][4].
What the trials measured for each, separately
Bremelanotide: the RECONNECT program was two identical phase 3, double-blind, placebo-controlled trials of 24 weeks, with 1,247 women in the safety population and 1,202 in the efficacy analysis, mean age 39 [10]. On the label, the FSFI desire score rose 0.5 versus 0.2 points on placebo in study 1 and 0.6 versus 0.2 in study 2 [1]. Integrated across both trials, desire improved by 0.35 points versus placebo (P<0.001) and desire-related distress fell [10]. The trials found no significant difference in the number of satisfying sexual events [10].
L-theanine: a 2026 meta-analysis of 31 randomized trials (1,168 people) found that a single 200 mg dose improved choice reaction time (SMD 0.51, 95% CI 0.25 to 0.77); the reduction in acute stress was small (SMD 0.31) and largely driven by trials at high risk of bias, anxiety results were inconsistent and non-significant apart from one study, and no serious adverse events were reported [2]. A 2025 meta-analysis of 18 sleep trials (897 participants, many using theanine in combination products) found small improvements in subjective sleep quality (SMD 0.43, 95% CI 0.04 to 0.83) and noted that few studies used pure theanine [11].
Side effects worth knowing about
Phase 3 rates for Vyleesi versus placebo: nausea 40.0% vs 1.3%, flushing 20.3% vs 0.3%, injection site reactions 13.2% vs 8.4%, headache 11.3% vs 1.9%, vomiting 4.8% vs 0.2%, dizziness 2.2% vs 0.5% [1]. Eighteen percent of Vyleesi patients stopped the trials because of adverse reactions versus 2% on placebo; serious adverse reactions were reported in 1.1% versus 0.5% [1]. Nausea was highest after the first dose (21%) and fell to about 3% with later doses; pre-treatment with oral ondansetron did not reduce it and is not recommended [1]. Focal hyperpigmentation of skin, gums or breasts, including the face, was reported by 1% of patients receiving up to 8 doses a month versus none on placebo, by 38% of patients after daily dosing for 8 days, and by a further 14% after 8 more consecutive days, with resolution not confirmed in all patients [1].
For theanine, safety in the 31-trial meta-analysis was assessed by comparing dropout rates and reasons with placebo, and no serious adverse events were reported [2]. One crossover trial found that 250 mg of theanine alone increased headache ratings [12]. A narrative review described daily doses of 200 to 400 mg for up to 8 weeks as safe [13].
Is there a spacing window?
No tested interval between the two exists. The label's only timing instruction is for bremelanotide: at least 45 minutes before anticipated sexual activity [1]. Bremelanotide peaks at a median of about 1 hour after a 1.75 mg injection and has a mean terminal half-life of about 2.7 hours [1]. L-theanine trial doses are typically 200 mg taken 30 to 60 minutes before testing, or 200 to 400 mg a day in stress studies [2][14].
Frequently asked questions
Can I take L-theanine with PT-141 (bremelanotide)?
Does L-theanine lower blood pressure enough to offset bremelanotide?
How long should I wait between L-theanine and a PT-141 injection?
Is compounded PT-141 Vyleesi?
What should I watch for after a Vyleesi dose?
References
Show all 14 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Gerolymos C, Saddier E, Boyer L, Fond G. Cognitive and affective effects of L-Theanine: a systematic review and meta-analysis of 31 randomized trials. Mol Psychiatry. 2026;31(11):6592-6602.
- Drugs@FDA: FDA-Approved Drugs.
- Yoto A, Motoki M, Murao S, Yokogoshi H. Effects of L-theanine or caffeine intake on changes in blood pressure under physical and psychological stresses. J Physiol Anthropol. 2012;31(1):28.
- Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW. Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology (Berl). 2008;195(4):569-77.
- Official web page.
- U.S. Food and Drug Administration.
- GRAS Notices.
- Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74(1):39-45.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- Bulman A, D'Cunha NM, Marx W, Turner M, McKune A, Naumovski N. The effects of L-theanine consumption on sleep outcomes: A systematic review and meta-analysis. Sleep Med Rev. 2025;81:102076.
- Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. The effects of L-theanine, caffeine and their combination on cognition and mood. Biol Psychol. 2008;77(2):113-22.
- Lopes Sakamoto F, Metzker Pereira Ribeiro R, Amador Bueno A, Oliveira Santos H. Psychotropic effects of L-theanine and its clinical properties: From the management of anxiety and stress to a potential use in schizophrenia. Pharmacol Res. 2019;147:104395.
- Williams JL, Everett JM, D'Cunha NM, Sergi D, Georgousopoulou EN, Keegan RJ, et al. The Effects of Green Tea Amino Acid L-Theanine Consumption on the Ability to Manage Stress and Anxiety Levels: a Systematic Review. Plant Foods Hum Nutr. 2020;75(1):12-23.